ME02364B - Jedinjenja za supresiju poremećaja perifernih nerava indukovanih anti-kancerogenim sredstvom - Google Patents

Jedinjenja za supresiju poremećaja perifernih nerava indukovanih anti-kancerogenim sredstvom

Info

Publication number: ME02364B
Authority: ME; Montenegro
Prior art keywords: suppressing; compounds; cancer agent; peripheral nerve; nerve disorder
Prior art date: 2010-01-27

Application number

MEP-2016-31A

Other languages

German (de)

English (en)

French (fr)

Inventor

Naomi Kitamoto

Original Assignee

Takeda Pharmaceuticals Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-01-27

Filing date

2011-01-26

Publication date

2016-06-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43770309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02364(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-01-26 Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co

2016-06-20 Publication of ME02364B publication Critical patent/ME02364B/me

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Emergency Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Toxicology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

MEP-2016-31A 2010-01-27 2011-01-26 Jedinjenja za supresiju poremećaja perifernih nerava indukovanih anti-kancerogenim sredstvom ME02364B (me)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2010015935		2010-01-27
PCT/JP2011/052077 WO2011093512A1 (en)	2010-01-27	2011-01-26	Compounds for suppressing a peripheral nerve disorder induced by an anti - cancer agent
EP11705047.6A EP2528598B1 (en)	2010-01-27	2011-01-26	Compounds for suppressing a peripheral nerve disorder induced by an anti - cancer agent

Publications (1)

Publication Number	Publication Date
ME02364B true ME02364B (me)	2016-06-20

Family

ID=43770309

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MEP-2016-31A ME02364B (me)	2010-01-27	2011-01-26	Jedinjenja za supresiju poremećaja perifernih nerava indukovanih anti-kancerogenim sredstvom

Country Status (41)

Country	Link
US (5)	US20130046000A1 (me)
EP (1)	EP2528598B1 (me)
JP (2)	JP6131046B2 (me)
KR (1)	KR20120118044A (me)
CN (2)	CN104744321A (me)
AR (1)	AR080024A1 (me)
AU (1)	AU2011211294B2 (me)
BR (1)	BR112012018434A2 (me)
CA (1)	CA2788150C (me)
CL (1)	CL2012002079A1 (me)
CO (1)	CO6592110A2 (me)
CR (1)	CR20120412A (me)
CY (1)	CY1117268T1 (me)
DK (1)	DK2528598T3 (me)
DO (1)	DOP2012000209A (me)
EA (1)	EA201290697A1 (me)
EC (1)	ECSP12012126A (me)
ES (1)	ES2560215T3 (me)
GE (1)	GEP20166441B (me)
HK (1)	HK1177423A1 (me)
HR (1)	HRP20160165T1 (me)
HU (1)	HUE027310T2 (me)
IL (1)	IL221066A (me)
MA (1)	MA34014B1 (me)
ME (1)	ME02364B (me)
MX (1)	MX2012008514A (me)
MY (1)	MY163936A (me)
NZ (1)	NZ601635A (me)
PE (1)	PE20121694A1 (me)
PL (1)	PL2528598T3 (me)
PT (1)	PT2528598E (me)
RS (1)	RS54591B1 (me)
SG (2)	SG182522A1 (me)
SI (1)	SI2528598T1 (me)
SM (1)	SMT201600103B (me)
TN (1)	TN2012000364A1 (me)
TW (1)	TWI481401B (me)
UA (1)	UA109540C2 (me)
UY (1)	UY33203A (me)
WO (1)	WO2011093512A1 (me)
ZA (1)	ZA201205681B (me)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2870822C (en) *	2012-04-27	2016-06-21	Nippon Zoki Pharmaceutical Co., Ltd.	Trans-2-decenoic acid derivative and drug containing same
MY189089A (en) *	2013-12-17	2022-01-25	Genentech Inc	Methods of treating cancers using pd-1 axis binding antagonists and taxanes
WO2016182036A1 (en)	2015-05-08	2016-11-17	Takeda Pharmaceutical Company Limited	Cyclic compounds
CN107771076A (zh)	2015-06-17	2018-03-06	豪夫迈·罗氏有限公司	使用pd‑1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法
CN109923101B (zh) *	2016-09-09	2021-03-09	武田药品工业株式会社	环状化合物
CN111465389B (zh) *	2017-09-07	2022-06-21	深圳信立泰药业股份有限公司	多西他赛共缀物的药物组合物及制备方法

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5804374A (en)	1980-12-05	1998-09-08	Massachusetts Insti. Technology	Nuclear factors associates with transcriptional regulation
US6410516B1 (en)	1986-01-09	2002-06-25	President & Fellows Of Harvard College	Nuclear factors associated with transcriptional regulation
JP2749042B2 (ja)	1986-01-09	1998-05-13	マサチユ−セツツインスチチユ−トオブテクノロジ−	転写調節に関与する核内因子
US4769372A (en)	1986-06-18	1988-09-06	The Rockefeller University	Method of treating patients suffering from chronic pain or chronic cough
US4785000A (en)	1986-06-18	1988-11-15	The Rockefeller University	Method of treating patients suffering from chronic pain or chronic cough
WO1988005083A1 (en)	1986-12-24	1988-07-14	Whitehead Institute For Biomedical Research	Method of inducible gene expression
WO1989007614A1 (en)	1988-02-12	1989-08-24	Massachusetts Institute Of Technology	Nuclear factors associated with transcriptional regulation
DE68910682T2 (de)	1988-03-01	1994-06-01	Whitehead Biomedical Inst	Aktivierung der nf-kappa b-vorstufe.
US5506231A (en)	1989-03-31	1996-04-09	The Children's Medical Center Corporation	Treatment of aids dementia, myelopathy and blindness
EP0465565B1 (en)	1989-03-31	1996-05-15	The Children's Medical Center Corporation	Treatment of aids dementia, myelopathy and blindness
US5334618A (en)	1991-04-04	1994-08-02	The Children's Medical Center Corporation	Method of preventing NMDA receptor-mediated neuronal damage
US5158883A (en)	1989-09-13	1992-10-27	Cornell Research Foundation, Inc.	Method of using aminoarginine to block nitric oxide formation in vitro
US5059712A (en)	1989-09-13	1991-10-22	Cornell Research Foundation, Inc.	Isolating aminoarginine and use to block nitric oxide formation in body
EP0557290A1 (en)	1990-08-23	1993-09-01	The Children's Medical Center Corporation	Treatment of aids dementia, myelopathy, peripheral neuropathy, and vision loss
US5614560A (en)	1991-04-04	1997-03-25	Children's Medical Center Corporation	Method of preventing NMDA receptor-mediated neuronal damage
WO1992017168A1 (en)	1991-04-04	1992-10-15	The Children's Medical Center Corporation	Method of preventing nmda receptor-mediated neuronal damage
US5455279A (en)	1991-04-19	1995-10-03	The Children's Medical Center Corporation	Regimen method of mediating neuronal damage using nitroglycerine
US6071876A (en)	1991-04-19	2000-06-06	Children's Medical Center Corporation	Method of preventing NMDA receptor complex-mediated neuronal damage
ATE182076T1 (de)	1991-04-19	1999-07-15	Childrens Medical Center	Verfahren zur vorbeugung nmda-rezeptorkomplex- vermittelter neuronaler schäden
EP0831809A4 (en) *	1995-06-07	2001-11-28	Sugen Inc	METHODS AND COMPOUNDS FOR INHIBITING ADAPTIVE PROTEIN / TYROSINE KINASE INTERACTIONS
US20020052019A1 (en)	1997-11-13	2002-05-02	Genentech Inc	Human toll homologue
US20020086368A1 (en)	1997-10-17	2002-07-04	Genentech Inc	Human toll homologues
US20030032090A1 (en)	1997-05-07	2003-02-13	Schering Corporation, A New Jersey Corporation	Human receptor proteins; related reagents and methods
ATE463502T1 (de)	1997-10-17	2010-04-15	Genentech Inc	Menschliche toll-homologe
US20040072138A1 (en)	1997-11-25	2004-04-15	Medical University Of South Carolina	Attenuation of ischemia/reperfusion injury
JP2002507384A (ja)	1997-11-25	2002-03-12	プリンストンユニヴァーシティー	アデノウイルスベクターの製造方法、それによって製造したベクターおよびその使用
WO1999026657A1 (en)	1997-11-25	1999-06-03	Musc Foundation For Research Development	Inhibitors of nitric oxide synthase
US20080275104A1 (en)	1997-11-25	2008-11-06	Musc Foundation For Research Development	Methods of treating juvenile type 1 diabetes mellitus
CN100432049C (zh)	1998-03-09	2008-11-12	武田药品工业株式会社	环烯衍生物、其制造方法和用途
KR100778256B1 (ko)	1999-08-06	2007-11-27	다케다 야쿠힌 고교 가부시키가이샤	치환 방향환 화합물, 그의 제조법 및 용도
SE9903930D0 (sv) *	1999-10-29	1999-10-29	Astra Pharma Inc	Novel compounds and a novel process for their preparation
DE60124504T2 (de)	2000-02-04	2007-09-20	Takeda Pharmaceutical Co. Ltd.	Stabile emulsionszubereitungen
EP1283849A2 (en)	2000-05-25	2003-02-19	Schering Corporation	Human receptor proteins; related reagents and methods
CA2685447C (en)	2000-08-10	2013-05-28	Takeda Pharmaceutical Company Limited	Pharmaceutical composition
EP1334966B1 (en)	2000-10-18	2011-05-04	Takeda Pharmaceutical Company Limited	Process for preparation of optically active sulfonamides and intermediates for their synthesis
US6762496B2 (en)	2000-11-30	2004-07-13	Tokuyama Corporation	Substrate and production method therefor
WO2002045750A1 (fr)	2000-12-08	2002-06-13	Takeda Chemical Industries, Ltd.	Medicaments combines
US7960416B2 (en)	2001-08-03	2011-06-14	Takeda Pharmaceutical Company Limited	Stable emulsion composition
KR20040099418A (ko) *	2002-04-08	2004-11-26	다케다 야쿠힌 고교 가부시키가이샤	중증 패혈증 예방 치료제
US8710095B2 (en)	2002-04-30	2014-04-29	Bionumerik Pharmaceuticals, Inc.	Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
WO2004074435A2 (en)	2003-01-30	2004-09-02	Emory University	Methods for identifying and administering agents that bias the immune response via dendritic cells
JP2006519020A (ja)	2003-02-27	2006-08-24	スリーエムイノベイティブプロパティズカンパニー	Ｔｌｒ介在生物活性の選択的調節
EP1613956A2 (en)	2003-03-25	2006-01-11	3M Innovative Properties Company	Selective activation of cellular activities mediated through a common toll-like receptor
JP2007505629A (ja)	2003-09-17	2007-03-15	スリーエムイノベイティブプロパティズカンパニー	Ｔｌｒ遺伝子発現の選択的調節
US8034619B2 (en)	2003-12-19	2011-10-11	University Of Cincinnati	Polyamides for nucleic acid delivery
MY147790A (en)	2005-04-28	2013-01-31	Takeda Pharmaceutical	Stable emulsion composition
ES2572755T3 (es)	2005-06-03	2016-06-02	Ono Pharmaceutical Co., Ltd.	Agente para la regeneración y/o la protección de nervios
US7618982B2 (en)	2005-12-19	2009-11-17	Nerviano Medical Sciences S.R.L.	Heteroarylpyrrolopyridinones active as kinase inhibitors
WO2007091790A1 (en)	2006-02-07	2007-08-16	Korea Institute Of Radiological & Medical Sciences	A composition for treating damage of central or peripheral nerve system
WO2007100650A2 (en)	2006-02-23	2007-09-07	Yale University	Drug resistance to plant alkaloids based upon myd88 status in a cell and methods of inhibiting signaling through the tlr-4:myd88 pathway
US7943588B2 (en)	2006-03-28	2011-05-17	Trustees Of Dartmouth College	Method for preventing or treating neuropathic pain
US8329420B2 (en)	2006-03-30	2012-12-11	Hiroshima University	Screening method for a substance that binds to an intracellular region of TLR4
WO2007123186A1 (ja) *	2006-04-20	2007-11-01	Takeda Pharmaceutical Company Limited	医薬
EP2018855A1 (en)	2006-05-15	2009-01-28	Takeda Pharmaceutical Company Limited	Pharmaceutical agent
JPWO2008004673A1 (ja)	2006-07-07	2009-12-10	武田薬品工業株式会社	シクロアルケン誘導体、その製造法および用途
EP1882687A1 (en) *	2006-07-27	2008-01-30	Amorepacific Corporation	Heterocyclic compounds useful as vanilloid receptor antagonists and pharmaceutical compositions containing the same
WO2008112887A1 (en)	2007-03-13	2008-09-18	Musc Foundation For Research Development	Methods of treating juvenile type 1 diabetes mellitus
US8399421B2 (en)	2007-03-30	2013-03-19	The Board Of Regents Of The University Of Texas System	Treatment for neuropathic pain due to spinal cord injury
WO2009059050A2 (en)	2007-10-30	2009-05-07	The Regents Of The University Of Colorado	Tlr modulators and methods for using the same
EP2262498A2 (en)	2008-03-10	2010-12-22	Vertex Pharmceuticals Incorporated	Pyrimidines and pyridines useful as inhibitors of protein kinases
JP5238381B2 (ja)	2008-07-07	2013-07-17	スタンレー電気株式会社	照明用車両用灯具
ES2519572T3 (es)	2009-09-23	2014-11-07	The Regents Of The University Of Colorado, A Body Corporate	Moduladores del receptor de tipo toll y usos de los mismos

2011
- 2011-01-26 MY MYPI2012003414A patent/MY163936A/en unknown
- 2011-01-26 US US13/574,848 patent/US20130046000A1/en not_active Abandoned
- 2011-01-26 HU HUE11705047A patent/HUE027310T2/en unknown
- 2011-01-26 PE PE2012001062A patent/PE20121694A1/es not_active Application Discontinuation
- 2011-01-26 EA EA201290697A patent/EA201290697A1/ru unknown
- 2011-01-26 SG SG2012051967A patent/SG182522A1/en unknown
- 2011-01-26 CA CA2788150A patent/CA2788150C/en not_active Expired - Fee Related
- 2011-01-26 JP JP2012533416A patent/JP6131046B2/ja active Active
- 2011-01-26 SG SG10201503402XA patent/SG10201503402XA/en unknown
- 2011-01-26 GE GEAP201112845A patent/GEP20166441B/en unknown
- 2011-01-26 UY UY0001033203A patent/UY33203A/es not_active Application Discontinuation
- 2011-01-26 AU AU2011211294A patent/AU2011211294B2/en not_active Ceased
- 2011-01-26 NZ NZ601635A patent/NZ601635A/xx not_active IP Right Cessation
- 2011-01-26 PL PL11705047T patent/PL2528598T3/pl unknown
- 2011-01-26 DK DK11705047.6T patent/DK2528598T3/en active
- 2011-01-26 TW TW100102774A patent/TWI481401B/zh not_active IP Right Cessation
- 2011-01-26 WO PCT/JP2011/052077 patent/WO2011093512A1/en active Application Filing
- 2011-01-26 MA MA35162A patent/MA34014B1/fr unknown
- 2011-01-26 AR ARP110100247A patent/AR080024A1/es unknown
- 2011-01-26 MX MX2012008514A patent/MX2012008514A/es not_active Application Discontinuation
- 2011-01-26 UA UAA201210137A patent/UA109540C2/uk unknown
- 2011-01-26 KR KR1020127021846A patent/KR20120118044A/ko active IP Right Grant
- 2011-01-26 EP EP11705047.6A patent/EP2528598B1/en active Active
- 2011-01-26 ME MEP-2016-31A patent/ME02364B/me unknown
- 2011-01-26 PT PT117050476T patent/PT2528598E/pt unknown
- 2011-01-26 CN CN201510072433.2A patent/CN104744321A/zh active Pending
- 2011-01-26 ES ES11705047.6T patent/ES2560215T3/es active Active
- 2011-01-26 RS RS20160076A patent/RS54591B1/en unknown
- 2011-01-26 BR BR112012018434A patent/BR112012018434A2/pt not_active IP Right Cessation
- 2011-01-26 CN CN201180015681.3A patent/CN102821763B/zh not_active Expired - Fee Related
- 2011-01-26 SI SI201130755T patent/SI2528598T1/sl unknown
2012
- 2012-07-17 TN TNP2012000364A patent/TN2012000364A1/en unknown
- 2012-07-23 IL IL221066A patent/IL221066A/en not_active IP Right Cessation
- 2012-07-25 DO DO2012000209A patent/DOP2012000209A/es unknown
- 2012-07-26 CL CL2012002079A patent/CL2012002079A1/es unknown
- 2012-07-27 ZA ZA2012/05681A patent/ZA201205681B/en unknown
- 2012-08-07 CR CR20120412A patent/CR20120412A/es unknown
- 2012-08-17 CO CO12140288A patent/CO6592110A2/es not_active Application Discontinuation
- 2012-08-27 EC ECSP12012126 patent/ECSP12012126A/es unknown
2013
- 2013-04-10 HK HK13104374.3A patent/HK1177423A1/zh not_active IP Right Cessation
- 2013-08-20 US US13/971,159 patent/US8901171B2/en not_active Expired - Fee Related
2014
- 2014-10-28 US US14/525,576 patent/US20150051256A1/en not_active Abandoned
2015
- 2015-04-02 US US14/676,947 patent/US20150203464A1/en not_active Abandoned
2016
- 2016-02-15 HR HRP20160165TT patent/HRP20160165T1/hr unknown
- 2016-02-19 US US15/047,965 patent/US20160166526A1/en not_active Abandoned
- 2016-03-04 CY CY20161100189T patent/CY1117268T1/el unknown
- 2016-03-18 JP JP2016056186A patent/JP2016175903A/ja active Pending
- 2016-04-12 SM SM201600103T patent/SMT201600103B/xx unknown

Also Published As

Publication number	Publication date
HUE027310T2 (en)	2016-10-28
JP2013518032A (ja)	2013-05-20
CN102821763A (zh)	2012-12-12
PL2528598T3 (pl)	2016-06-30
NZ601635A (en)	2013-06-28
AU2011211294A1 (en)	2012-09-20
US20160166526A1 (en)	2016-06-16
SI2528598T1 (sl)	2016-04-29
EP2528598B1 (en)	2016-01-13
TN2012000364A1 (en)	2014-01-30
BR112012018434A2 (pt)	2016-04-19
UY33203A (es)	2011-08-31
MA34014B1 (fr)	2013-02-01
DOP2012000209A (es)	2012-12-31
SG182522A1 (en)	2012-08-30
HK1177423A1 (zh)	2013-08-23
SMT201600103B (it)	2016-04-29
ES2560215T3 (es)	2016-02-17
US20150203464A1 (en)	2015-07-23
PT2528598E (pt)	2016-03-04
US20150051256A1 (en)	2015-02-19
AU2011211294B2 (en)	2014-11-13
CR20120412A (es)	2012-11-13
US20130046000A1 (en)	2013-02-21
ECSP12012126A (es)	2012-09-28
PE20121694A1 (es)	2012-12-06
TW201130482A (en)	2011-09-16
IL221066A (en)	2016-10-31
AU2011211294A2 (en)	2012-10-04
TWI481401B (zh)	2015-04-21
WO2011093512A1 (en)	2011-08-04
ZA201205681B (en)	2013-09-25
CA2788150A1 (en)	2011-08-04
DK2528598T3 (en)	2016-03-07
MX2012008514A (es)	2012-08-17
JP2016175903A (ja)	2016-10-06
CN104744321A (zh)	2015-07-01
US20130345304A1 (en)	2013-12-26
CN102821763B (zh)	2017-09-22
RS54591B1 (en)	2016-08-31
CA2788150C (en)	2017-06-06
UA109540C2 (uk)	2015-09-10
HRP20160165T1 (hr)	2016-03-11
CL2012002079A1 (es)	2012-12-21
US8901171B2 (en)	2014-12-02
JP6131046B2 (ja)	2017-05-17
CO6592110A2 (es)	2013-01-02
EA201290697A1 (ru)	2013-02-28
CY1117268T1 (el)	2017-04-26
GEP20166441B (en)	2016-03-10
AR080024A1 (es)	2012-03-07
MY163936A (en)	2017-11-15
SG10201503402XA (en)	2015-06-29
KR20120118044A (ko)	2012-10-25
EP2528598A1 (en)	2012-12-05

Publication	Publication Date	Title
IL233154A0 (en)	2014-08-03	compounds
GB201109763D0 (en)	2011-07-27	Compounds
GB201106395D0 (en)	2011-06-01	Compounds
ZA201306857B (en)	2015-05-27	Mesogen-containing compounds
GB201008584D0 (en)	2010-07-07	Novel iridium anti-cancer compounds
GB201122139D0 (en)	2012-02-01	Compounds
PL2581334T3 (pl)	2017-07-31	Osłona przeciwwypadkowa dla urządzeń dźwigowych
GB201107197D0 (en)	2011-06-15	Compounds
HUE043991T2 (hu)	2019-09-30	Hatáspotenciáló szer tumorellenes szerek számára
HRP20160165T1 (hr)	2016-03-11	Spojevi za suzbijanje poremeä†aja perifernog živca induciranog protutumorskim sredstvom
EP2699237A4 (en)	2014-11-12	THERAPY FOR LEUKEMIA
GB201110938D0 (en)	2011-08-10	Compounds
HK1191326A1 (en)	2014-07-25	Azaspirodecanone compounds
GB201110107D0 (en)	2011-07-27	Print gap compensation
GB201105659D0 (en)	2011-05-18	Compounds
GB201118613D0 (en)	2011-12-07	Compounds
GB201015784D0 (en)	2010-10-27	Anti-cancer compounds
AU2011900098A0 (en)	2011-01-27	Cyclopropylbenzopyran compounds as anti-cancer agents
GB201000771D0 (en)	2010-03-03	Compound for therapy
GB201121386D0 (en)	2012-01-25	Protecting papers for toilets
GB201015971D0 (en)	2010-11-03	Cure for epilepsy
AU2011094V (en)	2011-12-07	HF001 Hymenosporum flavum
GB201114058D0 (en)	2011-09-28	Cationic reactor
GB201120805D0 (en)	2012-01-11	Compounds
GB201119745D0 (en)	2011-12-28	Compounds